BioPharmSignal logoBioPharmSignal

Biotech News

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Theravance Biopharma (TBPH)Theravance BiopharmaEarnings

YUPELRI ® Collaboration Revenue increased 15% year-over-year 1, from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage All Hatch-Waxman litigation relating to YUPELRI ® has been resolved following settlement with Mankind Pharma in March

Related news

TBPHTheravance Biopharma2026-03-19 12:30 EST

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2025-11-10 21:05 EST

Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

XAIRBeyond Air2026-06-26 11:00 EST

Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update

XAIRBeyond Air2026-02-13 12:30 EST

Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

INSMInsmed2026-08-06 11:00 EST

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

RVPHReviva Pharmaceuticals2026-05-13 20:35 EST

Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights

INSMInsmed2026-05-07 11:00 EST

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

VERUVeru Inc2026-02-11 11:30 EST

Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

LUNGPulmonx2026-04-29 20:05 EST

Pulmonx Reports First Quarter 2026 Financial Results

LUNGPulmonx2026-03-04 21:06 EST

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

View all latest news

Theravance Biopharma

Respiratory Medicines Theravance Biopharma is a biopharmaceutical company whose principal economic asset is a respiratory medicine commercialized through a collaboration. YUPELRI YUPELRI, or revefenacin, is a once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease....

Recent company news

TBPHTheravance Biopharma2026-06-29 10:00 EST

THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT

TBPHTheravance Biopharma2026-05-07 12:30 EST

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-19 12:30 EST

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-03 13:30 EST

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions

TBPHTheravance Biopharma2025-11-20 16:00 EST

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

Stock data

Close
16.92 USD
Market cap
803.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States